CD274 and non-small cell lung carcinoma: Patients with metastatic non-oncogene addicted non-small cell lung cancer (NSCLC) are generally treated with systemic therapy (immune check-point inhibitors alone or in combination with chemotherapy according to anti programmed death-ligand 1 status -anti-PD-L1-) as first-line treatment approach (4).Pembrolizumab (anti-PD-L1) received approval in 2016 in the first line setting as a single agent for patients whose tumors have high PD-L1 expression (tumor proportion score of >50%).